{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:24:02Z","timestamp":1747196642694,"version":"3.40.5"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2020R1A2C2006282"],"award-info":[{"award-number":["2020R1A2C2006282"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>This study was performed to investigate the detection rate of <jats:italic>EGFR<\/jats:italic> T790M mutation by repeated rebiopsy, to identify the clinical factors related to repeated rebiopsy, and to assess survival outcomes according to the methods and numbers of repeated rebiopsies in patients with lung adenocarcinoma who received sequential osimertinib after failure of previous 1st or 2nd generation EGFR-tyrosine kinase inhibitors.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This retrospective study included patients with advanced-stage lung adenocarcinoma who were confirmed to have <jats:italic>EGFR<\/jats:italic> T790M mutation and to have received osimertinib from January 2020 to February 2021 at Samsung Medical Center. The presence of T790M mutation was assessed based on either plasma circulating tumor DNA (ctDNA) or tissue specimens.<\/jats:p>\n<jats:p>Results<\/jats:p>\n<jats:p>A total of 443 patients underwent rebiopsy, with 186 (42.0%) testing positive for the T790M mutation by the sixth rebiopsy. The final analysis included 143 eligible patients. Progression-free survival was not significantly different in terms of the methods (tissue: 13.3 months, 95% confidence interval [CI]: [9.4, 23.5] vs plasma: 11.1 months, 95% CI: [8.1, 19.4], p = 0.33) and numbers (one: 13.4 months, 95% CI: [9.4, 23.5] vs two or more: 11.0 months, 95% CI: [8.1, 14.8], p = 0.51) of repeated rebiopsies. Longer overall survival (OS) was found in patients in whom T790M was detected by tissue specimens rather than by plasma ctDNA (2-year OS rate: 81.7% for tissue vs 63.9% for plasma, p = 0.0038). Factors related to the lower numbers of rebiopsies included age and bone metastasis. Factor associated with T790M detection in tissue rather than in plasma was pleural metastasis, while advanced tumor stage was related to T790M confirmation in plasma rather than in tissue.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Repeated rebiopsy for T790M detection in patients with NSCLC can increase the detection rate of the mutation. Detection of T790M by plasma ctDNA might be related to poor survival outcomes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0310079","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T17:25:57Z","timestamp":1726766757000},"page":"e0310079","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib"],"prefix":"10.1371","volume":"19","author":[{"given":"Taeyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junsu","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Hye","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong-Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyungjong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hojoong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9765-9068","authenticated-orcid":true,"given":"Sang-Won","family":"Um","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"1","key":"pone.0310079.ref001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.lungcan.2011.12.014","article-title":"EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment","volume":"77","author":"W Brugger","year":"2012","journal-title":"Lung Cancer"},{"issue":"suppl_1","key":"pone.0310079.ref002","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.","volume":"29","author":"D Westover","year":"2018","journal-title":"Ann Oncol."},{"issue":"7","key":"pone.0310079.ref003","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"TS Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0310079.ref004","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.cllc.2017.07.002","article-title":"Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.","volume":"19","author":"T Kawamura","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"pone.0310079.ref005","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/1759-7714.13822","article-title":"Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first\/second generation EGFR-TKIs","volume":"12","author":"T Ninomaru","year":"2021","journal-title":"Thorac Cancer"},{"issue":"4","key":"pone.0310079.ref006","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.4143\/crt.2023.320","article-title":"Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?","volume":"55","author":"S Kim","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"8","key":"pone.0310079.ref007","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00432-021-03893-z","article-title":"First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study","volume":"148","author":"K Kudo","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"pone.0310079.ref008","doi-asserted-by":"crossref","first-page":"985","DOI":"10.4143\/crt.2021.857","article-title":"Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion.","volume":"54","author":"YJ Kim","year":"2022","journal-title":"Cancer Res Treat."},{"issue":"2","key":"pone.0310079.ref009","first-page":"e35","article-title":"When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival.","volume":"17","author":"WC Kwok","year":"2021","journal-title":"Asia Pac J Clin Oncol."},{"issue":"1","key":"pone.0310079.ref010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000502528","article-title":"Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA","volume":"98","author":"H Ikushima","year":"2020","journal-title":"Oncology"},{"issue":"4","key":"pone.0310079.ref011","article-title":"Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Na\u00efve Stage IV Non-Small Cell Lung Cancer Patients.","volume":"11","author":"BG Kim","year":"2022","journal-title":"J Clin Med"},{"issue":"13","key":"pone.0310079.ref012","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1002\/cam4.2485","article-title":"Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment","volume":"8","author":"PL Su","year":"2019","journal-title":"Cancer Med"},{"issue":"50","key":"pone.0310079.ref013","doi-asserted-by":"crossref","first-page":"29525","DOI":"10.18632\/oncotarget.25705","article-title":"Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer","volume":"9","author":"E Ichihara","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"pone.0310079.ref014","first-page":"e12128","article-title":"Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.","volume":"12","author":"I Pereira","year":"2020","journal-title":"Cureus"},{"issue":"6","key":"pone.0310079.ref015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/ajco.13935","article-title":"Real-world data on efficacy and safety of osimertinib in non-small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy.","volume":"19","author":"Y Wang","year":"2023","journal-title":"Asia Pac J Clin Oncol."},{"issue":"5","key":"pone.0310079.ref016","doi-asserted-by":"crossref","first-page":"e000919","DOI":"10.1136\/esmoopen-2020-000919","article-title":"Understanding EGFR heterogeneity in lung cancer","volume":"5","author":"A Passaro","year":"2020","journal-title":"ESMO Open"},{"issue":"11","key":"pone.0310079.ref017","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/JTO.0000000000000647","article-title":"Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI","volume":"10","author":"A Hata","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"10","key":"pone.0310079.ref018","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.","volume":"16","author":"C Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"pone.0310079.ref019","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13046-020-01601-2","article-title":"Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples","volume":"39","author":"M Russano","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"pone.0310079.ref020","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1016\/j.cllc.2020.02.021","article-title":"Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.","volume":"21","author":"R Minari","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"pone.0310079.ref021","doi-asserted-by":"crossref","first-page":"585284","DOI":"10.3389\/fonc.2020.585284","article-title":"Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis.","volume":"10","author":"T Zhu","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0310079.ref022","doi-asserted-by":"crossref","first-page":"22372","DOI":"10.1038\/s41598-022-26131-z","article-title":"Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer","volume":"12","author":"Q Li","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0310079.ref023","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s12885-020-07202-8","article-title":"Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer","volume":"20","author":"W Ouyang","year":"2020","journal-title":"BMC Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T17:26:10Z","timestamp":1726766770000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310079"}},"subtitle":[],"editor":[{"given":"Hamidreza","family":"Montazeri Aliabadi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0310079","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}